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1. Introduction 
Marijuana, hashish and other psychoactive products obtained from Cannabis sativa are the 
most produced and trafficked illicit drugs around the world (CND, 2006).  
It is difficult to estimate the moment when man began to use some of the preparations from 
cannabis sativa. Thus, the reported consumption of the plant and its derivatives appears as an 
ancient practice, in many parts of the globe, from India to China, extending from the Middle 
East (Persia, Asia Minor and Egypt) to Africa, through the Christian culture, until the West 
(Ellenhorn & Barceloux, 1988; Ladrón de Guevara & Moya Pueyo, 1995; Rodríguez-Vicente 
et al., 1995). The effects that these compounds have on an individual brain have been 
addressed in several instances, such as religious practice, or simply in the search of 
pleasurable sensations. Cannabis sativa has been used in China nearly for five thousand 
years, being its cultivation related to fiber, oil and seeds production (Camp, 1936). However, 
Asians also knew its narcotic action in the seventh century BC, incorporating cannabis in 
their religious rituals and as a therapeutic agent, in neurological and psychiatric diseases 
(Mechoulam, 1991).  
Cannabis consumption came to the Iberian Peninsula across North Africa, once conquered by 
the Arabs. But its presence was ephemeral, not achieving a significant presence on all the 
Christian kingdoms (Nahas, 1982). Ramazzini, an eighteenth century physician, studied its 
potential toxic effects, but it was O'Shaughnessy, an Irish surgeon who lived in India as a 
British colonial army doctor, the first scientific researcher to carry out pharmacological 
studies with the plant and the promoter of its application in therapy (Nahas, 1973; 
O’Shaughnessy, 1842). Thus, in 1842, after reviewing its therapeutic use in India and after 
some experimental research on animals, he introduced Cannabis in Europe (Robson, 2001). 
Indeed, this doctor was impressed with the outstanding application of this drug as a muscle 
relaxant, anticonvulsant, analgesic and anti-emetic. However, due to its uncontrollable 
power, there was a rapid decline in its therapeutic value. Thus, in 1840, the French physician 
Jacques-Joseph Moreau, considered as the father of psychopharmacology, described in his 
book "Du Haschisch et de l'alienation mentale, Psychologiques études" (1845), the toxic effects of 
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hallucinogens, calling attention to the danger of its use, since it could produce individual 
and social deterioration, and also cause addiction. Since 1971, the use of cannabis was 
controlled by the so-called "Drug Abuse Act”, which forbade the use of both medical herbs 
and their active constituents, cannabinoids. Its use had already been removed from medical 
practice since 1932, the year it was eliminated from the British Pharmacopoeia. Ten years 
later, it was removed from the United States and 34 years later, from the Indian 
Pharmacopoeia. The controversy over its hallucinogenic actions on the brain has eclipsed its 
possible medical uses (Evans, 1997). 
Cannabis consumption as a drug of abuse begins to spread in some European countries in 
the 60's and was popularized in the '70s and '80s. It is estimated that, presently, cannabis 
world production mainly occurs in America (46%), followed by Africa (26%) and by Asia 
(22%) (UNODC, 2007). 
2. Botany: Cannabis sativa L 
The genus Cannabis is composed of a single plant species, Cannabis sativa Linn., classified by 
Linnaeus in 1753, based on specimens from India but with different shapes. The 
morphological characteristics, fiber production, oils or resins, and even the size, are so 
varied that botanical classification becomes very difficult (Astolfi et al., 1979; Ellenhorn & 
Barceloux, 1988; Rodríguez-Vicente et al., 1995). Some botanists argue for the existence of 
three species: Cannabis sativa, Cannabis indica and Cannabis ruderalis, while others admit the 
existence of only two. Cannabis sativa, hemp common name (Cannabis means hemp; sativa 
means sowing or cultivating), is a plant endemic to a geographic area between the Caspian 
and Black Seas, passing through Persia and India, growing up in the Far East since ancient 
times. Under normal conditions it can have one or two meters height reaching, in its highest 
development stage, up to four meters. Cannabis sativa has been cultivated, for centuries, due 
to the hemp present on the stems, seeds and oil and due to its biological active substance 
(9-Tetrahydrocannabinol) in the higher parts with flowers, varying its chemical 
composition according to the different parts of the plant. The plant growth favourable 
conditions are a moist soil with high nitrogen content, being the clayey soils the worse 
conditions to its growth (Wilsie & Reddy, 1946). This plant has been adapting to different 
climates, adaptation accompanied by morphological changes, especially related to the leaf 
(Eckler & Miller, 1912). In fact, plant cannabinoids chemistry is much more complicated 
than the pure 9-THC and thus, multiple effects can be expected due to the additional 
cannabinoids presence as well as other chemicals (Turner et al., 1980).  
3. Consumption patterns 
The potency of cannabis products is determined by its 9-THC content, usually given as a 
percentage of 9-THC. ElSohly et al. (2000) estimated, in a study performed between 1980 
and 1997 in confiscated marijuana samples, that 9-THC percentage was between 1.5 and 
4.2%, being, however, sometimes higher. The highest percentages were found in marijuana 
samples (29.9%), hashish (52.9%) and oil (47.0%). In 2005, the average or typical level of 9-
THC Cannabis resin at the retail level ranged between 1% and 17%, being this variation 
range difficult to explain given the common origin of most European resin. 
Over the past 20 years, more modern farming methods and crops increasingly sophisticated 
have been developed, leading to increased potency on Cannabis products. In the so-called 
"flower power" days from the 60s and 70s, every marijuana cigarette contained about 10 mg 
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of 9-THC. Currently, a cigarette can have about 150 mg 9-THC (9-THC between 6 and 
20%, corresponding to 60-200 mg/cigarette) or 300 mg, if mixed with hashish oil. Thus, 
nowadays, a cannabis consumer is frankly exposed to higher doses than in previous 60 or 70 
decades (Gold, 1991; Mendelson, 1987; Schwartz, 1991). However, the 9-THC content also 
varies extraordinarily, depending on the different Cannabis sources and preparations. In 
fact, there are several Cannabis preparations, leading to different consumption forms and 
different names (even according to different countries), as well as different power degrees 
(Astolfi et al., 1979; Ellenhorn & Barceloux, 1988; Rodríguez-Vicente et al., 1995): the herb, 
consisting of several parts of the plant, presents a variable active ingredients quantity 
depending on the part of the plant used for its preparation. It is usually smoked alone, but it 
may be mixed with tobacco. It has different names according to the country (among others, 
in Portugal and in Mexico, marijuana; in Morocco and Spain, grifa or marihuana; in South 
Africa, dagga; in Great-Britain, hemp; in Brazil, maconha); the resin, also called haxixe, hachis, 
hashis, hash, charas or chira, is five to eight times more potent than the herb, being the product 
spontaneously secreted by plants in small drops, thus corresponding to the resin of the 
plant. It can also be extracted from the plant through organic solvents. It can be smoked in 
special pipes or  in cigarettes, being the resin, after burning, mixed with tobacco; the hash 
oil, obtained by hot extraction of the plant or  by hashish extraction with organic solvents 
and consequent evaporation, has, as a concentrated resin, a high power. 
 
Class 
Nº compound
in the plant 
Class 
Nº 
compound 
in the plant 
 
Cannabinoids 
Cannabigerol (CBG) 
Cannabichromene (CBC) 
Cannabidiol (CBD) 
1(9)-THC 
1(8)-THC 
Cannabiciclol (CBL) 
Cannabielsoin (CBE) 
Cannabinol (CBN) 
Cannabinodiol (CBND) 
Cannabitriol (CBT) 
Other Cannabinoids 
Nitrogen compounds 
Quaternary bases 
Amides 
Amines 
Alkaloids spermidines 
Amino Acids 
Proteins, glycoproteins & enzymes 
Hydrocarbons 
Simple alcohols 
Simple aldehydes 
 
61 
6 
4 
7 
9 
2 
3 
3 
6 
2 
6 
13 
20 
5 
1 
12 
2 
18 
9 
50 
7 
12 
 
Simple ketones 
Simple acids 
Fatty acids 
Simple esters and lactones 
Steroids 
Sugars and similar 
Monosaccharides 
Disaccharides 
Polysaccharides 
Cyclitols 
Amino-sugars 
Terpenes 
Monoterpenes 
Sesquiterpenes 
Diterpenes 
Triterpenes 
Mixture of terpenoid 
Non-cannabinoid phenols 
Flavonoid glycosides 
Vitamins 
Pigments 
Total 
 
13 
20 
12 
13 
11 
34 
13 
2 
5 
12 
2 
103 
58 
38 
1 
2 
4 
16 
19 
1 
2 
421 
Table 1. Compounds classes found in Cannabis sativa (Honório & Silva, 2006). 
www.intechopen.com
 
Forensic Medicine - From Old Problems to New Challenges 
 
218 
4. Chemical structure and properties 
Cannabis sativa present a large number of different chemicals, as illustrated in Table 1, being 
cannabinoids the main class. These compounds vary in number and quantity, according to 
the climate, soil type, variety cultivated and the way the crop was performed.  
The observed variations also depend on the part of the plant used for their extraction, the 
drugs preparation method for the consumption, as well as its storage conditions (Waller, 
1971). Cannabis contains about 421 different chemical compounds, including 61 
cannabinoids (Turner et al., 1980). During the consumption by smoking, more than 2000 
compounds can be produced by pyrolysis. Eighteen different classes of chemicals, including 
nitrogen compounds, amino acids, hydrocarbons, sugars and fatty acids can contribute to 
the single known pharmacological and toxicological properties of cannabinoids (Huestis, 
2002). The term "cannabinoid" was attributed to the compound’s group with 21 carbon 
atoms present in Cannabis sativa, also added to their carboxylic acids, analogs and possible 
transformation products (Honório & Silva, 2006). They are usually formed by three rings, 
cyclohexene, benzene and tetrahidropiran. Some are the responsible for the power of the 
various psychoactive plant preparations (Mendelson, 1987). 
 
 
Fig. 1. Cannabinoid 3D chemical structure (a) and linear structures of two numbering 
systems used for cannabinoid compounds (b) and (c) (Honório & Silva, 2006). 
The chemical structure of a cannabinoid type is shown in Figure 1, indicating the main 
numbering systems in the literature. The first report of proven isolation of the cannabis 
active ingredient in its pure form, 9- Tetrahydrocannabinol or simply 9-THC, dates from 
1964, by Gaon and Mechoulam. Due to the great interest in the effects caused by the 
compounds extracted from cannabis, several studies have been conducted with the aim of 
identifying possible relationships between their chemical structure and their biological 
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activity. Cannabinol (CBN) was the first known cannabinoid, a phenolic compound resin 
obtained by Wood and collaborators in 1896. Canh, in 1932 got its  cleansing in the 
crystalline acetate form, demonstrating that it is a phenolic derivative of dibenzopiran. 
Later, thanks to Cahn (1933) and Adams (1940), the structure of the CBN was established. 
In 1940, Adams and Baker isolated another cannabis resin principle, which designated as 
Cannabidiol (CBD). Both CBN and CBD have lack active and enhancer effects. Later, in 
1970, Mechoulam demonstrated that in the plant, there is a cannabinoids biosynthesis cycle 
that relates them, proving that the different components isolated by different authors were 
intermediate products. Although it is known that 9-THC has six isomers (as an 
isomerization result), only the isomers 9-THC e 8-THC were isolated from the natural 
product. Of all the natural cannabinoids, 9-THC is the most active compound, existing in 
the two forms mentioned above. 
5. Cannabinoids properties 
In fact, 9-THC is the psychoactive cannabinoid with higher potency. Concerning the other 
cannabinoids present in the plant and about which there is some information: 
i. 8-THC presents a very similar pharmacological profile to that of 9-THC, although 
lower, and thus, it has been studied for its possible use in drugs without psychoactive 
effects. This compound is only present is some plant varieties, being its concentration 
much lower when compared to 9-THC (Mechoulam et al., 1992). 
ii. CBN (Canabinnol) also has some psychoactive properties, among which are those 
related to the 9-THC discriminative stimuli (Järbe & Mathis, 1992).  This activity is, in 
animals, about one tenth of the described for 9-THC. However, the results in humans 
have been quite contradictory, since some authors found that, by its intravenous 
administration, the CBN produces similar effects to those described for 9-THC (Pérez-
Reyes et al., 1973), contrary to those observed by Hollister (1974), who didn’t detect any 
effect when administration was performed orally. 
In fact, when comparing with 9-THC, CBN has a higher affinity for the CB2 cannabinoid 
receptors than for the CB1 cannabinoid receptors (Munro et al., 1993). Being CB2 a 
peripheral receptor, CBN seems to participate in the immune system modulation, having 
been attributed, a long ago, to cannabinoids. 
iii) CBD (Cannabidiol) is a cannabinoid practically devoid of psychoactive properties, since 
it is not capable to disconnect, from a CB1 receptor, neither an agonist nor an antagonist 
(Thomas et al., 1998). Since it is not a psychoactive substance, a detailed research has been 
developed in order to evaluate its possible clinical effects, and it has been described at least 
one case where its oral administration resulted in an effective long-term treatment of a 
psychosis framework (Zuardi et al., 1995). 
We can, thus, say that cannabinoids properties depend on their chemical structure. Minimal 
variations in the THC molecule components can cause major changes in its activity. 
6. Toxicokinetics 
6.1 Absorption 
9-THC absorption varies depending on the administration route. Inhalation is the most 
common administration route among cannabis consumers (smoke inhalation from water 
pipes or cigarettes), although there are also references to its use either orally (beverages or 
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food ingestion) or parenteral, providing a rapid and efficient method for drug distribution 
in the body. Cannabis sativa preparations (hashish, marijuana) are mainly consumed in 
cigarettes, and approximately 30% of the 9-THC present in marijuana cigarettes or hashish 
are destroyed by pyrolysis during smoking (Huestis, 2002). The combustion heat leads to 
THC acids transformation to 9-THC, as well as 8-THC synthesis from CBD. 
Simultaneously, the existent 9-THC is largely destroyed by smoking, originating CBN. This 
suggests that the maximum amount of 9-THC absorbed during smoking does not exceed 
70% of the 9-THC content existent in the cigarettes. The intense pleasure effects can be 
produced due to the almost immediate CNS exposure to the drug. In fact, after smoking, 
there is a rapid absorption of 9-THC through the respiratory tract into the bloodstream. 
However, about 18% of an inhaled 9-THC dose is absorbed (Ohlsson et al., 1980), being an 
oral dose significantly less effective (Nahas, 1979). Moreover, 9-THC bioavailability after 
inhalation is highly variable (Barnett et al., 1982, Lindgren et al. 1981; Ohlsson et al. 1980; 
Ohlsson et al., 1982, Pérez-Reyes et al., 1982), because it is affected, not only by the specific 
characteristics of the cigarette and its corresponding combustion, but also by the inhalation 
intensity, administration duration, among other factors. Experienced smokers inhale more 
efficiently than inexperienced people, being the 9-THC bioavailability, in a marijuana 
cigarette with approximately 1-2% of the drug, between 16 and 40% for chronic users and 
between 13 and 14% for occasional users (Ohlsson et al., 1982). Cannabinoids oral ingestion 
leads to lower plasma 9-THC levels than by inhalation, i.e., gastrointestinal absorption 
represents, approximately, one third of the achieved via inhalation. Orally, its bioavailability 
is reduced due to the gastric fluid acidity, the intestinal metabolism, as well as the first-pass 
enterohepatic system effect (Agurell et al., 1986). It has been observed that in acidic 
conditions (at a pH above 4.0), 9-THC isomerizes, giving rise to 8-THC or 9-
hidroxihexahidrocanabinol. At a more acidic pH, the rupture of the pyran ring occurs, 
leading to the formation of several replaced cannabinoids. These changes could possibly 
explain the loss of 9-THC activity after oral administration due to the acidic pH of the 
stomach (Garret et al., 1978). However, large intra-and inter-individual differences may also 
contribute to uncertainty in the effective dose distribution (Agurell et al. 1986; Ohlsson et al., 
1982). 
9-THC can be detected in plasma within seconds after inhaling the smoke of a marijuana 
cigarette (aHuestis et al., 1992), with plasma peak levels reached about 7 to 8 minutes after 
starting smoking, with euphoria and a maximum heart acceleration at about 20 minutes after 
(Perez-Reyes et al., 1982). However, after an oral administration, absorption is slow and 
irregular (Blaw et al. 1984; Ohlsson et al., 1980, Wall et al., 1983), reaching the highest 9-THC 
plasma levels about 45 minutes after ingestion and remaining relatively constant for 4 to 6 
hours (Wall et al., 1983). The clinical effects begin 30-60 minutes after oral consumption, 
reaching a peak 2-3 hours after ingestion (Isbell et al., 1967) and it can hardly be correlated 
with plasma levels. Bioavailability is reduced in about 20-40% after oral administration 
(Ohlsson et al., 1980, Wall et al., 1983) due to the drug degradation within the gastrointestinal 
tract (Perez-Reyes et al., 1973). We can, thus, say that a greater oral amount of 9-THC is 
required to achieve the same physiological effects as by inhalation. Moreover, after oral 
administration, a gradual increase of its plasma concentration is produced and it can last for 
several hours, delaying the onset of their psychoactive effects (Cone and Huestis, 1993). 
6.2 Distribution 
Studies on 9-THC bioavailability showed considerable differences between pulmonary and 
oral routes. Smoking seems to be the most effective method for drug administration. 9-THC 
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entrance in the blood and its subsequent distribution to the tissues is very rapid, with very 
similar kinetics to the ones obtained after an intravenous administration. 
Only 3% of the 9-THC detected in the blood is in its free form. About 97 to 99% is bound to 
plasma proteins, primarily (60%) to lipoproteins ( and ) (Hunt & Jones, 1980; Wall et al., 
1983) and the remain to albumin at a 6: 4 ratio. For this reason, the free concentration in 
plasma is actually very low (Klansner et al., 1975), being in the erythrocytes in only about 
10% (Garret & Hunt, 1974; Widman et al., 1974). With a large distribution volume (10L/Kg), 
high 9-THC lipid solubility leads to increased concentration and prolonged retention of the 
drug in fatty tissues (aJohansson e col., 1989), like the nervous tissue. Indeed, concerning its 
effective distribution in the tissues, 9-THC is pulled out from the plasma to the tissues in 
about 70% (Hunt and Jones, 1980), although the distribution (which only occurs for the free 
fraction) is limited by the low concentration of its free form in the blood. Therefore, this 
distribution will depend on each organ blood flow. Consequently, given the greater 
distribution through more vascularized organs, and due to its high lipid solubility, brain is 
the organ where higher 9-THC concentrations are achieved: 3 to 6 times higher than in 
plasma and just in 30 minutes. 
Initial studies in animals, after 9-THC administration, marked with 14C, showed that 9-
THC concentrations in the tissues (in many cases of 9-THC and metabolites) were higher in 
the lung, liver, kidney, heart, stomach, spleen, fat gray, placenta, thyroid, pituitary and 
mammary gland, when compared with brain or blood (Kreuz & Axelrod, 1973; Leighty, 
1973; Ryrfeldt et al., 1973, Siemens et al., 1979). Later studies in rabbits also suggested that 
the highest 9-THC concentrations can be detected in fat and in the heart, but not in the 
brain (Leuschner et al., 1986). The relatively low 9-THC levels found in the brain can be, 
mainly due to its strong irrigation and consequent rapid and constant 9-THC 
transportation from the blood into and out of the brain. Afterwards, it distributes by adipose 
tissue, which is, together with the spleen, its major deposit, three days after administration 
(Rawich et al., 1979). Several weeks are needed for the drug to be completely eliminated, 
even after discontinuing the administration (Kreuz & Axelrod, 1973). A slow cannabinoids 
release from fatty tissues and a significant enterohepatic recirculation contributes to the long 
half-life in plasma, which has been estimated to be around 4 days, or even more in chronic 
marijuana users (Johansson et al., 1988). Moreover, cannabinoids may remain the double of 
the time, in the plasma of regular smokers (Mason et al., 1983). In fact, this gradual 
cannabinoids release from the tissues to the bloodstream extends its presence in the blood 
and subsequent entry into the brain, being this one possible explanation for the absence of a 
withdrawal syndrome when the administration is suspended (Agurell et al., 1986). 
6.3 Metabolism 
Only a minimal amount of 9-THC is eliminated from the body in its original form (with 
less than 1% excreted by the kidneys in its unchanged form), and most appear as 
metabolites in faeces (68%) or in urine (12%). The drug is also present in other tissues and 
biological fluids such as saliva, hair and sweat. 9-THC is almost completely metabolized in 
the liver, although metabolism can also occur in the lung and intestine (Agurell et al., 1986). 
In man, 9-THC metabolism involves allylic oxidation, epoxidation, aliphatic oxidation, 
decarboxylation and conjugation reactions. The allylic oxidation at C-8 and C-11 and 
aliphatic oxidation at the side chain lead to the formation of hydroxylated metabolites. The 
mono- and di-hydroxy metabolites are then oxidized to form acids and hydroxy acids. 
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Thus, in studies performed in vivo and in vitro, it was been shown that 9-THC is primarily 
metabolized in its hydroxylated compound by the hepatic microsomal enzymes 
(cytochrome P450) by allylic hydroxylation at carbon 11. 9-THC is metabolized in 11-
hydroxy-9-tetrahydrocannabinol (9-THC-OH) (Iribarne et al., 1996, Matsunaga et al., 
1995), considered to be his true active metabolite (Lemberger et al., 1970). Similarly, 8-THC 
follows a very comparable degradation pathway (Agurell et al., 1981), being rapidly 
hydroxylated to 11-hydroxy-8-tetrahydrocannabinol in the liver (Matsunaga et al., 1995). 
Hydroxylation at position 11 is the most important 9-THC metabolism reaction in most 
species, including humans. The 11-hydroxy-9-tetrahydrocannabinol (9-THC-OH) has a 
similar pharmacological activity and potency than 9-THC. 9-THC-OH is quantifiable in 
plasma 10 minutes after a 9-THC intravenous administration. However, by oral 
administration, the relationship between this metabolite and the main drug is about 5 times 
higher than the one measured after an intravenous administration (Lemberger et al., 1971). 
Even so, plasma concentrations achieved after oral administration can range from 50 to 
100% when compared to the detected 9-THC concentrations (Wall et al., 1983). After 
smoking marijuana, the detected 9-THC-OH concentrations are lower, about 10% of the 9-
THC concentrations (aHuestis et al., 1992; Wall et al., 1983), reaching the maximum 9-THC -
OH peak (Cmax) in approximately 13 minutes after smoking, with maximum concentrations 
of, around, 7 ng/ml, after a single marijuana cigarette. 
After 9-THC administration, its psychological effects begin to occur about 10 to 20 minutes 
after, although the effects caused by 9-THC-OH are only evident about 3-5 minutes later 
(Lemberger et al., 1973). This difference may be due to their pharmacokinetic properties, 
particularly different distribution and transfer into the nervous system, since their effects are 
equivalent. This can also explain the fact that, after an oral administration, the 
pharmacodynamic effects are higher than those induced with the same 9-THC 
concentration, but reached after smoking (Ohlsson et al., 1980). However the 
biotransformation process continues, and the active metabolite 9-THC-OH may oxidize, 
giving rise to the corresponding carboxylic acid (9-THC-COOH) or return to hydroxylate 
itself. In this second case, it converts to 8, 11-dihydroxy-9-THC, i.e., 11-hydroxy derivative 
transformation occurs in the liver into dihydroxy-9-THC. These compounds are then 
transformed into other hydroxylated metabolites, more polar, inactive, which are then 
excreted in urine and faeces. The 9-THC-OH oxidation leads to the production of an 
inactive metabolite, 11-nor-9-carboxy-9-tetrahydrocannabinol (9-THC-COOH) (Lemberger 
et al., 1972), identified in plasma, urine and faeces (Wall & Perez-Reyes, 1981, Wall et al., 
1983). Subsequently, conjugation with the glucuronic acid can occur, being 9-THC-COOH 
and its glucuronide conjugates the main end biotransformation products in many species, 
including humans (Halldin & Widman, 1983). Renal clearance of these polar metabolites is 
always slow due to its extensive plasma protein binding (Hunt & Jones, 1980). After 
smoking, 9-THC-COOH plasma concentrations gradually increase, becoming higher than 
9-THC concentrations shortly after smoking, whereas 9-THC plasma concentrations 
decrease very rapidly (aHuestis et al., 1992). Hence, the 9-THC-COOH detection time is 
much higher than for 9-THC or for 9-THC-OH. The CBD (Cannabidiol) metabolism is 
quite complex, with the possible production of almost 83 metabolites (Harvey, 1991). The 
proportions of these compounds also vary between species (Harvey & Mechoulam, 1990). 
The metabolism of CBN (cannabinol) is less complex than for other cannabinoids. In most 
species, the hydroxylation at C-11 predominates, although there is also an important side 
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chain hydroxylation. The excreted metabolites are mainly 11-hydroxy-CBN, the CBN acid-
11-oic acid and its hydroxylated side chain analogues (Brown and Harvey, 1990). 
6.4 Elimination 
Over 65% of the drug is excreted in faeces (68%), with approximately 13% excreted in urine 
(Wall et al., 1983). A total of 80-90% is excreted in 5 days, mainly in the hydroxylated and 
carboxylated metabolites forms. Only minimal amounts are excreted in their free forms 
(Hunt & Jones, 1980, Wall et al., 1983). Therefore, we can say that both 9-THC and 8-THC 
are not eliminated in their free form but in the form of metabolites (THC-OH and/or THC-
COOH) or by glucuronic acid conjugation, producing different glucuronides. This process 
takes place in the liver involving several enzymes. The glucuronides formed are highly 
hydrophilic and therefore easily eliminated in the urine. 9-THC-COOH metabolite has been 
detected in either urine or faeces (Wall & Perez-Reyes, 1981), while 9-THC-OH 
predominates in the faeces. In fact, biliary excretion, and the consequent elimination 
through the faeces is the major route of unconjugated metabolites elimination (Wall et al., 
1983), although most of the metabolites are reabsorbed from the gut. This enterohepatic 
circulation, which leads to more than 15% of the metabolites (Nahas, 1979), is responsible for 
the delay in the final active metabolites disposition, contributing to a prolonged excretion 
and to its accumulation among different body tissues. 
In urine a total of 20 9-THC metabolites were identified, two glucuronic acid and 18 
unconjugated acids forms. Indeed, the 9-THC-COOH glucuronide conjugate is the primary 
urinary metabolite formed (Williams & Moffat, 1980). All other unconjugated acids 
metabolites identified in urine, excepting the 11-nor-9-9-THC-COOH, undergo oxidation or 
are degraded, forming varied carboxylated or hydroxylated metabolites. The average life of 
the inactive metabolites is about seven days, staying in the body for up to thirty days 
(Sutheimer et al., 1985). Some authors even accept the metabolites presence in urine within 
72 days after use (Ellis et al., 1985), despite having an estimated 9-THC plasma elimination 
time of 4 days (aJohansson et al., 1989). 
7. Action mechanism 
For a long time ago, some hypotheses had been proposed to explain 9-THC action 
mechanism, suggesting that 9-THC may exert its actions through a nonspecific drug 
interaction with cell membranes and intracellular organelles (Hillard et al., 1985; Martin, 
1986). However, it is notoriously difficult to delineate the precise action mechanisms of 
cannabinoids, given the evident 9-THC activity in several places, including the receptors 
for opiates and benzodiazepines, as well as marked effects on prostaglandins synthesis and 
protein metabolism (Burstein et al. 1982; Welch & Eads, 1999). Cannabinoids inhibit 
macromolecular metabolism according to the dose, presenting a wide effects range on the 
enzyme systems, neurotransmitters and hormone secretion (Bloom, 1982, Chakravarty et al. 
1975; Dalterio et al. 1977; Dalterio et al. 1987; Dill & Howlett, 1988; Pertwee, 1988). These 
numerous and diffuse effects supported the hypothesis of a nonspecific interaction. 
However, with cannabinoids pharmacology knowledge advance, it became obvious that 
some structural aspects would be required for the cannabinoids activity, including the 
receptor binding in the target cells (Mechoulam, 1991). 
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7.1 Cannabinoid receptors 
Nowadays it is clearly known that cannabinoids act through its interaction with specific 
endogenous receptors, discovered by Devane et al. (1988) and later colonized. Indeed, a 
specific protein receptor was discovered, named CB1 (central receptors) (Matsuda et al., 
1990, Munro et al., 1993), in the mouse nerve cells, being now known that it can also be 
found in the brain of the mouse, guinea pig, dog, monkey, pig and man, and peripheral 
nerves. The biology and behaviour associated with brain areas are consistent with the 
behavioural effects produced by cannabinoids (Table 2). The highest density of receptors is 
found in the basal ganglia cells, involved in coordinating body movements. 
 
A) - Brain regions where cannabinoid receptors are abundant 
Brain regions Tasks associated with the region 
Basal ganglia 
 Cerebellum 
 Hippocampus 
 Cerebral Cortex 
Motion control 
 Coordination of body movements 
 Learning, memory, stress 
 Cognitive functions 
B) - Brain regions where cannabinoid receptors are moderately concentrated 
Brain regions Tasks associated with the region 
Hypothalamus 
 
Amygdale 
 Backbone 
 Brainstem 
Maintenance of body functions (temperature, electrolyte 
balance, reproductive function) 
Emotional response, fear 
 Peripheral sensation, including pain 
 Sleep, temperature regulation, motor control 
Table 2. Brain regions where cannabinoid receptors are abundant or moderately 
concentrated and functions associated with these areas (Honório & Silva, 2006). 
CB1 receptors mediate the majority of the cannabinoids responses in the central nervous 
system (CNS), being abundant in the cerebral cortex, hippocampus, amygdale, basal 
ganglia, cerebellum, and thalamus (Ashton, 2001; Robson, 2001). The high receptors density 
in the caudate nucleus and cerebellum are consistent with the marked cannabinoids effects 
in motor behaviour (Romero et al. 1995; Sanudo-Pena et al., 2000). The significant link 
within the cerebral cortex and hippocampus explains the marked cannabinoids effects on 
perception, cognitive aspects, memory, learning, endocrine function and body temperature 
regulation (Chait & Perry, 1994, Compton et al. 1993; Hampson & Deadwyler, 1999). 
The CB1 receptors location in the hippocampus supports that cannabinoids play an import 
role in appetite and energy regulation. This supposition is strengthened by its presence in 
important peripheral organs, as the GI tract, liver, skeletal muscle and adipose tissue. 
Despite being primarily viewed as a central receptor (presence in the nervous tissue) 
(Herkenham et al., 1990), this CB1 receptor was also found in the adipose tissue (Bensaid et 
al., 2003), myocardium (Bonz et al. 2003), vascular endothelium (Liu et al., 2000) and in 
sympathetic nerve terminals (Ishac et al., 1996). 
In 1993, Munro et al. identified a second cannabinoid receptor, the CB2 receptor, present, 
preferentially, in the immune system cells, outside the CNS (peripheral receptor). Efforts 
have been made to improve the chemical manipulation of cannabinoids, to maximize the 
selectivity for these receptors CB2, avoiding the psychoactive effects (Robson, 2001). This 
distinctive peripheral cannabinoid receptor seems to play a major role in 
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immunomodulation (Lynn & Herkenham, 1994; Reggio et al., 1997), showing a significant 
anti-inflammatory and immunosuppressive activity. It has already been postulated the 
existence of a third receptor - CB3 - (Fride et al., 2003), but the receptor itself has not been 
colonized yet. It is believed now that the two cannabinoid receptors - CB1 e CB2 - are 
responsible for many biochemical and pharmacological effects produced by the majority of 
cannabinoid compounds (Matsuda et al., 1990). The functional differences existent between 
the two receptors types are still not known, but structural differences raise that possibility. 
In 1986, Howlett et al. showed that 9-THC inhibited the intracellular enzyme adenylyl 
cyclase (AC) and that this inhibition occurred only in the presence of a G-protein complex, 
this is, in the presence of a cannabinoid receptor, which is a typical member of the largest 
known receptors family: G-coupled protein, containing seven transmembrane domains 
(Glass & Northup, 1999; Howlett et al., 1991). The body's cells respond in different ways 
when a ligand interacts with the cannabinoid receptor. The receptor intracellular surface 
interacts with G proteins that regulate effectors’ proteins such as AC, or calcium and 
potassium channels, and via a protein kinase activated by mitogen (Bayewitch et al. 1996; 
Bidaut-Russell et al. 1990). 
7.2 Endogenous cannabinoids 
The cannabinoid receptors discovery prompted the search for an endogenous ligand to 
which the receptors naturally interact. For each biological receptor (in this case, a brain 
receptor) there is probably an endogenous agonist, i.e., a compound naturally produced by 
the body that interact with the receptor. The first endogenous cannabinoid discovered was 
arachidonoylethanolamine known as anandamide, derived from the Sanskrit word ananda, 
meaning "happiness." This substance was isolated from pig brain, by Devane et al. (1992), 
and these authors observed that, being chemically distinct from the cannabinoid plant, 
compared with 9-THC, it has a moderate affinity for CB1 receptors, but with most of the 9-
THC actions, although having a short action period. In general, the affinity of anandamide 
for cannabinoid receptors is only ¼ to ½ the affinity displayed by 9-THC, these differences 
being related to the cells or tissues used in those studies as well as with the other 
experimental conditions (Smith et al. , 1994). Anandamide mimics 9-THC action since it 
binds to both receptor subtypes, CB1 and CB2, and has a similar pharmacological activity, 
despite having little power to exert some effects (Fride & Mechoulam, 1993; Howlett , 1995; 
Mechoulam & Hanus, 1996; Pertwee 1995). This ligand was found in several regions of the 
human brain (hippocampus, striatum and cerebellum) where CB1 receptors are abundant, 
suggesting the involvement of endogenous cannabinoids in the brain functions controlled 
by these areas. However, substantial concentrations of anandamide are also found in the 
thalamus, a brain area with few CB1 receptors (Di Marzo et al., 1994). An interesting fact is 
that anandamide was also found in small amounts in other parts of the body such as the 
spleen, where there are high concentrations of CB2 receptors, and heart (Ameri, 1999; 
Fowler, 2003; Howlett, 1998; Pop, 1999). It may, therefore, be concluded that the molecule 
anandamide has both central and peripheral impact (Di Marzo et al., 2000). Although 
Deutsch and Chin (1993) have proposed a biosynthetic pathway for anandamide, it appears 
that this gets rid of cell membranes followed by depolarization due to a calcium influx (Di 
Marzo, 1998, Evans et al., 1992). Also Sugiura et al. (1995) examined the effects of 
anandamide and another endogenous compound, 2-araquidonil glycerol (2-AG) in 
connection with a specific cannabinoid receptor, assuming that the latter substance can also 
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be an endogenous ligand with relevant role in the brain. Under normal conditions, the 
endocannabinoid system appears to be tonically active; instead, the endocannabinoids are 
produced as needed, act locally and are rapidly inactivated by cellular uptake and 
enzymatic hydrolysis (Giuffrida et al., 2001).  
In addition to the identification of these ligands there were also synthesized some specific 
CB1 receptors antagonists (Rinaldi-Carmona, 1994) and CB2 (Portier et al., 1999). The 
SR141716 (now under the name of Rimonabant) was the first specific CB1 antagonist 
receptor, with high affinity, blocking the acute effects of 9-THC and other CB1 agonists in 
vitro and in animals (Adams et al. 1998; Rinaldi-Carmona, 1994). In 2001, Huestis et al., 
conducting the first clinical studies on the pharmacokinetic and pharmacodynamic effects of 
Rimonabant, administered orally, in combination with cannabis smoking, demonstrated that 
cannabis administration alone produced the expected physiological responses with the 
consequent intoxication reflection and, when combined with Rimonabant, a dose-dependent 
blocking effect of cannabis was observed. Significant advances in cannabinoid research have 
opened new frontiers leading to an increasing interpretation of their effects and the role of 
endogenous cannabinoids in man.  
8. Pharmacodynamic effects 
Due to their action mechanism, cannabinoids exert multiple conducts, acting in almost all 
biological systems. Its activity is multiple and complex due to the variety of psychoactive 
products present in the plant whose toxic and pharmacological actions may overlap or be 
additive. The main factors influencing the toxicity of these substances are: dose, 
administration route, individual's personality, dependence degree, concomitant 
administration of other substances and chronological stage of the administration. 
The behavioural and physiological cannabinoids effects have been increasingly reported 
over the recent decades (Adams & Martin, 1996; Dewey, 1986; Jones, 1987), including 
euphoria and relaxation feelings, times reaction changes, lack of concentration, learning and 
memory changing or mood states (such as panic reactions and paranoia). The spectrum of 
cannabinoids behavioural effects is unique, leading to a consequent classification of these 
drugs as stimulants, tranquilizers, or hallucinogenic (Benowitz et al. 1979; Hollister, 1986; 
Law et al., 1984). Other common physiological effects include increased appetite, dry mouth, 
vasodilation and decreased respiratory rate. Cannabinoids may affect the immune and 
endocrine systems, producing lung damage and influencing neonatal and child 
development of (Chandler et al., 1996, Day et al., 1991, Fried et al. 1999; Fried & Smith, 2001; 
Tashkin et al., 1991). The physiological effects of cannabinoids are most relevant for the 
main systems are: 
a. Effects on Cardiovascular System 
The 9-THC effects of on the cardiovascular system depend on the dose, with a decrease in 
heart rate with low doses and increased at higher doses (which may exceed 160 beats/min). 
This substance may also lead to a decrease in contractile force and lead to progressive 
reduction in coronary blood flow (Tashkin et al., 1978). Acute administration of 
cannabinoids in humans produces vasodilation and tachycardia, resulting in an overall 
effect on systemic blood pressure (Huestis et al., 1992). However, the unrelenting use of 9-
THC results in hypotension mediated by CB1 receptors and bradycardia (Benowitz et al., 
1975, Lake et al., 1997). Endocannabinoids induce vasodilation by acting, directly, on CB1 
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receptors located in the arterial smooth muscle of the brain (Gebremedhin et al., 1999). 
Moreover, the same occurs at other vessels, through an increased synthesis of nitric oxide 
(NO) endothelium-dependent (Deutsch et al., 1997). These and many other effects on CV 
can be an increased risk for individuals with pre-existing heart disease (especially in 
patients with heart failure and coronary), as already reported, for example, in acute cardiac 
accidents cases, often fatal for Cannabis consumers (Ashton, 2001). 
b. Metabolic Effects  
The endocannabinoid system appears to play a crucial role in regulating metabolism and 
body composition. The appetite stimulation (especially for sweets) and dry mouth due to 
decreased salivary secretion are usually adverse reactions produced in cannabis consumers.  
The consequent weight loss may suppose that there is a changing in glucose metabolism. 
However, several studies show that there is no agreement on the glucose levels change 
(Hollister et al. 1968; Lindemann, 1933, Weil et al., 1969). However, its effect on other 
metabolic processes is of great significance. Thus, control of food intake and body 
composition results from complex interactions between the adipocytes, the mesolimbic 
system, hypothalamus and gastrointestinal tract. The hunger feeling often existent in 
consumers is mediated by an intestinal hormone, ghrelin, which is produced in most 
circumstances of weight loss. Moreover, leptin, an endogenous hormone, can reduce food 
intake. The serum concentration of this hormone is directly proportional to the degree of 
adiposity, but obese people have lower sensitivity to the hormone. A protein produced in 
adipose tissue, adiponectin stimulates fatty acid oxidation and body weight decrease, being 
its concentration lower in obese individuals (Considine et al., 1996, Cummings et al. 2002; 
Fruebis et al. 2001). 
Both cannabinoid receptors and their endocannabinoids ligands are present in tissues 
related to food intake. The concentration of endocannabinoids in the hypothalamus 
decreases after leptin administration (Di Marzo et al., 2001). Studies in animals (rodents) 
showed that the CB1 receptor agonists are potent inducers of hyperphagia (Jamshidi et al., 
2001, Kirkham et al., 2002, Williams et al., 1999), while their antagonists prevent such effect 
(Di Marzo et al., 2001). In another study, it was found that mice do not express CB1 
receptors resulting in spontaneous calories reduction (Cota et al., 2003). For all these 
interferences at the cannabinoid system, metabolic modulation of this pathway has been 
considered to be a greater possibility for therapeutic intervention in obesity (Feliciano et al. 
2007; Francischetti et al., 2006). 
c. Effects on Pulmonary System 
Inhaling the smoke of marijuana cigarettes (or 9-THC) produces acute bronchodilation in 
healthy subjects and asthmatics, bronchodilation that may last at least one hour (Tashkin et 
al. 1977; Vachon et al., 1973). It is important to note that cannabis smokers have a higher lung 
cancer risk than tobacco consumers because of the high aromatic hydrocarbons content in 
marijuana smoke, which has higher concentrations of irritant substances, such as sterols, 
terpenes, among others (Fehr and Kalant, 1972). Comparing a normal about five times 
tobacco cigarette with a marijuana cigarette, it is estimated that the latter produces more 
carboxyhemoglobin, with consequent maintenance increase in the respiratory tract (Benson 
& Bentley, 1995, Wu et al., 1988). Chronic use of cannabis cigarettes is associated with 
bronchitis and emphysema. It is estimated that 3-4 cannabis cigarettes per day equals more 
than 20 tobacco cigarettes a day, with subsequent evidence of acute and chronic bronchitis 
(Benson and Bentley, 1995). 
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d. Effects on Vision 
The administration of cannabis cigarettes in normal individuals causes a slight constriction of 
the pupil, preserving light reflection, marked congestion of conjunctiva vessels, tearing and 
intraocular pressure reduction related to dose. In fact, vasodilatation and redness of the 
conjunctiva is a characteristic sign of cannabis use (Paton & Pertwee, 1973). Other changes 
include colour perception and light adaptation changes (Ohlsson et al., 1980). 
9. Cannabinoids and driving influence 
Experimental studies have been repeatedly demonstrating 9-THC effects on an individual 
cognitive function and psychomotor skills, influencing learning and information acquisition, 
changing the individual's memory capacity, coordination and reaction times (Chait & Pierri, 
1992; Kurzthaler et al. 1999; Leire et al., 1989). The biggest concern with cannabinoids acute 
effects is related to road traffic or labour accidents (Hall, 2001). Indeed, 9-THC acute effects 
on cognitive function and psychomotor skills have been subject of extensive study, noting 
that, at doses between 40 and 300 mg/kg, cannabinoids can cause a dose-dependent 
reduction in tasks that require memory use, reaction times, in motor functions and 
coordination (Ameri, 1999; Curran et al. 2002; D 'Souza et al. 2004; Hall & Solowij 1998; 
Hampson & Deadwyler 1999; Lewek et al. 1998; Lichtman et al. 2002; Ramaekers et al., 
2004). 
The impaired state induced by cannabinoids has been studied by several authors in tests 
performed on drivers (Lamers & Ramaekers, 2001; Ramaekers et al., 2000), demonstrating 
that their driving risk effects increase with the dose, being more extensive and persistent in 
activities that require more careful attention. There is an enormous concern, both in the 
European Union and in the United States of America (USA) regarding the link between 
cannabinoids consumption and traffic accidents. However, from a legal standpoint, the 
evaluation and interpretation of the corresponding accuracy is still a big challenge, since the 
association between 9-THC levels and the accidents risk is not perfectly clear. Currently, 
some authors claim that there is very little scientific evidence demonstrating that 9-THC or 
9-THC-COOH detection in body fluids can be used as impairment evidence in any 
circumstance. They assume, for example, that 9-THC or its metabolite can be detected in 
the body for days after smoking cannabis and thus, their presence may be indicative of a 
previous consumption and not of a recent use, not being certain that the presence of the 
drug in the body indicates an impairment state (Drummer et al., 2003). Papafotiou et al. 
(2005), through experimental studies in volunteers, acknowledged that the negative 
relationship between driving performance and 9-THC levels found in blood is due to the 
fact that the 9-THC peak concentrations are achieved in the CNS a few time after being 
achieved in blood. Similarly to what occurs with benzodiazepines, where the maximum 
influenced state is observed one hour after peak plasma concentrations are reached (Rush & 
Griffiths, 1996), the maximum influenced state after 9-THC consumption occurs after 
achieving the maximum blood concentration. On the other hand, it has been shown that the 
influence and accident risk due to recent cannabis increases with dose, with an influenced 
state already present at low doses, being even worse at higher concentrations (Ramaekers et 
al., 2004). Note, however, that it is not perfectly acknowledged how to correlate the plasma 
9-THC levels variation with driver's behaviour, although this relationship has been 
simulated in experimental behavioural cannabinoid pharmacodynamics and 
pharmacokinetics studies. Ramaekers et al. (2006) developed, thus, a study in cannabis 
consumers, concluding that the impairment sate was progressively higher with increasing 
www.intechopen.com
 
Cannabinoids: Forensic Toxicology and Therapeutics 
 
229 
9-THC concentrations. They admitted that already with 9-THC concentrations between 2 
and 5 ng/ml there was significant influence state; when 9-THC was detected between 5 
and 10 ng/ ml, about 75 to 90% of the individuals were under the influence and over 30 
ng/ml, there was a  were 100% influence. Cone and Huestis (1993) also conducted a similar 
research and concluded that the ability to drive may be influenced one hour after 
consumption, during the 9-THC elimination phase, even when the concentrations decrease 
to 13 ng/ml. Berghaus et al. (1995) go even further, stating that with 6 ng/ml of 9-THC the 
information processing is already affected, with attention and vision changes at 9 ng/ml 
and 12 ng/ml, respectively. They demonstrated that the 9-THC driving influence is mainly 
evident in the first two hours after consumption, leading to performance changes, with 
higher prevalence on attention, psychomotor and cognitive capacities.  
10. Therapeutic perspectives of the endocannabinoid system modulation 
Endocannabinoids (EC) are involved in several physiological functions, among which, 
special attention has been given to the regulation of appetite by central mechanisms and its 
influence on obesity (van Thuijl et al., 2008; Kirkham, 2009). Considering these innovative 
findings, the research for new pharmacological agents has drastically increased and the 
discovery of rimonabant, a synthetic antagonist of CB1 receptors, has confirmed the 
important role of endocannabinoid system on the modulation of food ingestion and 
energetic balance (Butler et al., 2009). These facts led to the first clinical studies using 
rimonabant as a new tool against obesity and its associated metabolic disorders. However, 
psychiatricside-effects, namely central, which include increased risk of depression and even 
suicide, US Food and Drug Administration declined permission for rimonabant, and in 
October 2008, rimonabant was also suspended across the EU. After rimonabant withdrawal, 
other CB1 antagonist drugs have also tested, including the taranabant, which was associated 
with weight loss in rats and in humans (Fong et al., 2007; Addy et al., 2008). However, due 
also to central side effects, including anxiety and depression, the clinical trials were stopped 
in October 2008 (EMEA. The European Medicines Agency recommends suspension of the 
marketing authorisation of Acomplia: http://www.emea.europa.eu 2008). 
Although several other different influences of endocannabinoids have been discussed 
during the last years, including in inflammation, diabetes, cancer, affective and 
neurodegenerative diseases, and epilepsy (Izzo et al., 2009), the most recent findings are 
related to their cardiovascular actions (Durst & Lotan, 2011), which seem to be very ample 
bust also complex. In vivo experiments with rats have demonstrated the action of 
anandamide and 2-AG on the development of atherosclerotic plaque, as well as an effect on 
heart rate, blood pressure, vasoactivity and energy metabolism (action in dyslipidemia and 
obesity). Recent studies with an antagonist of CB1 receptors showed that the modulation of 
ECS can play an important role in reducing cardiovascular risk in obese and dyslipidemic 
patients. Similarly, studies in rats have demonstrated the action of CB2 receptors in 
adhesion, migration, proliferation and function of immune cells involved in the 
atherosclerotic plaque formation process. The ECS have been implicated in hypotensive 
stages associated with hemorrhagic chock, both endotoxic and cardiogenic, and even to 
advanced liver cirrhosis; on the other hand, recent evidence suggests that ECS plays an 
important role in cardiovascular regulation associated with hypertension, as well as a 
protective role in ischemia grafting. The development of atherosclerotic plaque and the 
metabolic stages associated to obesity are also matter of study of possible ECS 
pharmacomodulation.  
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Effects on myocardial ischemia/reperfusion and preconditioning 
Initial studies used isolated preparations of heart to study the role of ECS in myocardial 
ischemia/reperfusion (I/R) and preconditioning. The involvement of ECS in 
preconditioning induced by the endotoxin (lipopolysaccharide: LPS) against the injury 
induced by I/R on myocardium has been implicated for the first time in 2001, based on the 
hypothesis that LPS could increase the production of endocannabinoids in inflammatory 
cells (Varga et al., 1998). A 90 minutes of low flow ischemia followed by 60 minutes of 
reperfusion with normal flow in isolated rat hearts pretreated with LPS was compared with 
a saline solution. The pretreatment with LPS reduced the infarct size and improved 
functional recovery after reperfusion when compared with control group, which could be 
attenuated by SR144528 (CB2 antagonist), but not by rimonabant (CB1 antagonist), 
suggesting the involvement of myocardium CB2 in the cardioprotection induced by LPS 
(Lagneux & Lamontagne, 2001). In a subsequent study, in which the preconditioning was 
triggered by heat stress, the SR144528 also abolished the effect of reducing the infarct size, 
unlike rimonabant (Joyeux et al., 2002). 
These early studies suggested that the protection created by the preconditioning induced by 
heat stress or by LPS was mediated by the action of endocannabinoids in the CB2 receptors. 
In contrast, when preconditioning was induced by a brief period of ischemia (5 minutes), the 
blockade of CB1 and CB2 receptors did not raise the abolition of protection, and both 
receptors have been implicated in preserving endothelium-dependent vasodilatation 
induced by serotonin (Bouchard et al., 2003). The palmitoylethanolamide or the 2-AG, but 
not anandamide, when added to perfused isolated rat hearts offer protection against 
ischemia by reducing myocardial damage and infarct size and by improving the functional 
recovery of myocardium (Lepicier et al., 2003). The SR144528 completely blocked the 
cardioprotective effect of palmytoylethanolamide and 2-AG, whereas rimonabant only 
inhibited, partially, the effect of 2-AG (Lepicier et al., 2003). Similarly, ACEA and JWH015 
(CB1 and CB2 agonists) also reduced the size of the infarct in this model (Lepicier et al., 
2003). In contrast, it was found that anadamida’s effect of reducing infarct area could also be 
antagonized by CB1 and CB2 antagonists; however, the same could not be mimicked by 
selective CB1 and CB2 agonists, suggesting an involvement of a different site of CB1 and 
CB2 receptors. Another recent study, which used a model of delayed preconditioning in 
rats, induced by transdermal treatment of nitroglycerin (as an NO donor) for 24 hours, 
suggested that the protective effect of nitroglycerin against myocardial infarction is 
mediated trough CB1 receptors. Nitroglycerin increased the concentration of 2-AG in 
myocardium, but did not increase anandamide (Wagner et al., 2006). These pioneer studies 
implicated a possible contribution of CB2 functional receptors in cardiomyocytes and the 
endothelial cells responsibility, at least in part, on the protective effects of preconditioning. 
Indeed, subsequent studies showed the presence of CB2 receptors in myocardium, in 
cardiomyoblast cells and in endothelial cells with different origins ((Mukhopadhyay et al., 
2003; Blazquez et al., 2003). Concurrently with the beneficial effect of the activation of CB2 
receptors in cardiomyocytes, a recent study showed that THC protected cardiomyoblast 
cells H9c2 submitted to hypoxia in vitro, presumably trough the activation of CB2 receptors 
and increased NO production (Shmist et al., 2006). 
In an ischemia/reperfusion injury model in rats, both anandamide and HU-210 decreased 
the incidence of ventricular arrhythmias and reduced the size of the infarct, presumably 
trough the activation of CB2 receptors but not CB1 receptors (Krylatov et al., 2001). In an 
myocardic I/R injury model induced by ligation of coronary artery in rats, the reduction of 
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the second myocardic injury depending on leucocytes subsequent to the initial I/R injury 
was attributed to the activation of CB2 receptors, since the protection given by WIN 55.212-2 
could be prevented by AM630, but not by AM251 (a CB1 antagonist) (Di Filippo et al., 2004). 
Two recent studies in myocardial infarct models, acute and chronic, in rats, showed that 
cannabinoids contribute to hypotension and cardiac depression associated to cardiogenic 
acute shock, which could be attenuated by antagonists of CB1 receptors (Wagner et al., 
2003). 
Overall, despite the role of CB1 receptors and of endocannabinoids in the protection given 
by the preconditioning against myocardic I/R, the issue remains controversial, 
recommending further investigation namely using mice with deletion of genes and more 
selective agonists of CB2 receptors. However, the findings that imply CB2 receptors’ 
importance, presumably in both endothelial and inflammatory cells and perhaps in 
cardiomyocytes, are quite encouraging.  
Cerebral ischemia/reperfusion (cerebrovascular accident) 
The ECS may constitute an essential mechanism of neuroprotection, in both acute forms of 
neuronal injury, such as stroke or brain trauma, and in several chronic neurodegenative 
disorders, including multiple sclerosis, Parkinson’s disease, Hungtington’s disease, 
Alzheimer’s disease and amyotrophic lateral sclerosis (Pacher et al., 2006a). Although the 
exact mechanisms of this neuroprotection are not yet completely understood, several 
processes dependent and independent of CB receptors seem to be involved: 1) modulation 
of the immune responses and release of inflammatory mediators by CB1, CB2 and not 
CB1/not CB receptors in neurons, astrocytes, microglia, macrophages, neutrophils and 
lymphocytes (Klein, 2005); 2) modulation of synaptic plasticity and excitatory glutamatergic 
transmissions via presynaptic CB1 receptors (Freund et al., 2003); 3) activation of 
cytoprotective signaling pathways (Pacher et al., 2006a); 4) modulation of calcium 
homeostasis and excitability trough interactions with calcium channels, potassium and 
sodium, gap junctions and intracellular calcium reserves, and with NMDA receptors 
(Freund et al., 2003); 5) central hypothermia mediated by CB1 receptors, presumably by the 
reduction of the metabolic rate of needed oxygen; 6) antioxidant properties of cannabinoids 
(Hampson et al., 2000); 7) modulation of endothelial activity and inflammatory response, 
leucocytes mobilization, adhesions to the endothelium, transmigration and activation 
presumably through CB2 receptors. The first evidence of a neuroprotective effect of 
cannabinoids has emerged in research studies on cerebrovascular accident, in which was 
used the non psychoactive cannabinoid dexanabinol/HU-211 that exerts its effect through 
CB1/CB2 independent mechanisms, in cerebral ischemia models in vivo in rats and gerbils 
(Pacher et al., 2006a). Further studies also investigated the neuroprotective effects of CB1 
receptors stimulation with synthetic agonists. The synthetic cannabinoid WIN 55.212-2 
attenuated the neurological damage in the hypothalamus resulting from cerebral global and 
transient ischemia in rats and reduced infarct size after permanent focal cerebral ischemia 
induced by cerebral middle artery occlusion, when it was administrated 40 minutes before 
or 30 minutes after occlusion, in a dependent way from CB1 receptors, since the protective 
effect was prevented by rimonabant (Nagayama et al., 1999). WIN 55.212-2, as well as 
anandamide and 2-AG, did also confer protection to cultured cortical neurons submitted to 
hypoxia and glucose deprivation in vitro, but these effects proved to be insensitive to 
antagonists of CB1 and CB2 receptors (Nagayama et al., 1999). 
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In models of cerebral middle artery occlusion in rats, the agonist BAY38-7271 reduced the 
size of the infarct, even when administered intravenously 4 hours after the occlusion 
(Mauler et al., 2002). The pre-treatment with rimonabant partially attenuated the effect of 
HU-210, indicating the involvement of CB1 receptor. However, the protective effect of HU-
210 could be completely abolished by warming the animals’ body until the controls 
temperature, showing that hypothermia mediated by CB1 receptors was responsible for the 
beneficial effects observed (Leker et al., 2006). Similarly, hypothermia mediated by CB1 
receptors was responsible for the neuroprotective effects of THC in a model of cerebral 
ischemic injury in rats (Hayakawa et al., 2004), and in a model of global cerebral ischemia 
injury in rats (Louw et al., 2000). Concurrently with the neuroprotection mediated by CB1 
receptors, mice without CB1 receptors showed an increased neurotoxicity to NMDA and 
high mortality levels in permanent focal cerebral ischemia, and an increased infarct area, 
with neurological deficits more severe after transient focal cerebral ischemia and decreased 
blood flow in brain in ischemic penumbra during reperfusion, when compared with 
controls under the same aggressions (Parmentier-Batteur et al., 2002). In contrast, several 
recent studies do not support the neuroprotective role of endocannabinoids in the activation 
of CB1 receptors. In fact, rimonabant and LY320135 (CB1 receptors antagonist) reduced the 
size of the infarct and improved the neurological function in a cerebral ischemia model in 
rats, induced by brain middle artery occlusion (Muthian et al., 2004), while low doses of 
WIN 55,212-2 showed no protective effects (Muthian et al., 2004). Recent studies have 
evaluated the effect of selective CB2 agonists (O-3853, O-1966) in a model of cerebrovascular 
accidents. CB2 agonists significantly decreased cerebral infarct and improved motor 
function after cerebral middle artery occlusion for one hour, followed by 23 hours of 
reperfusion in rats, by attenuation of the increased mobilization of leucocytes and their 
adherence to vascular endothelial cells induced by transient ischemia (Zhang et al., 2007). 
The role of CB2 receptors in I/R injury was also supported by the increased accumulation of 
CB2-positive macrophages derived from resident microglia and/or from invading 
monocytes resulting from I/R cerebral injury (Ashton et al., 2007). 
In general, it seems clear that both agonists and antagonists of CB1 receptors may play a 
neuroprotective effect on cerebral I/R injury. The reason for the contradictory effects of the 
pharmacological blockade versus genetic “knockout” of CB1 receptors is still unclear, but 
could be related with effects that are independent from CB1 antagonists, and that’s the 
reason why this subject requires further clarification. In the case of CB2 agonists, the most 
likely protection mechanism is the reduction of increased leukocyte infiltration, mobilization 
and adhesion to vascular endothelial cells and consequent activation, in a process induced 
by I/R transient injury. 
Circulatory shock (organ/body ischemia and/or ischemia/reperfusion) 
In addition to its well-known immunologic and neurobehavioral actions,  cannabinoids and 
their synthetic endogenous analogs exert complex cardiopressant and vasodilator effects, 
which were implicated in the mechanisms underlying hypotension associated to 
hemorrhagic shock, cardiogenic and septic, advanced liver cirrhosis, cirrhotic 
cardiomyopathy, heart failure induced by doxorubicin and shock associated to necrotizing 
pancreatitis  (Lamontagne et al., 2006; Ashton & Smith, 2007; Ribuot et al., 2005; Moezi et al., 
2008; Sarzani, 2008). These depressant effects of the cardiovascular system could be 
prevented or reversed by the pretreatment with CB1 receptor antagonists, and they have 
been analyzed in many recent studies. CB receptors antagonists (eg. rimonabant, AM281, 
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AM251 and SR144528) prolonged the survival in septic shock or in necrotizing pancreatitis 
(Varga et al., 1998), increasing mortality in hemorrhagic (Wagner et al., 1997) and 
cardiogenic (Wagner et al., 2001) shock, despite the increase in blood pressure. One possible 
explanation for this intriguing controversy is the hypothesis that vasodilatation mediated by 
endocannabinoids can provide a survival value by increasing tissues oxygenation, 
neutralizing the excessive sympathetic vasoconstriction triggered by hemorrhage or by 
myocardium infarct, which could be avoided by blocking CB1 receptors. In contrast, the 
blockade of CB1 receptors could increase survival in endotoxic shock by preventing the 
primary hypotensive response to LPS (Pacher et al., 2006a). Even more complicated is the 
fact that, in hemorrhagic shock, both cardiogenic and septic, UH-210, WIN 55,212-2 and 
THC (CB agonists) are able to improve endothelial function and/or survival (Varga et al., 
1998). Since cardiovascular failure and dysfunction in many of the cited studies are 
triggered by I/R injury and/or ischemia, and consequently oxidative/nitrosative stress and 
inflammatory response associated to the activation of several cell death pathways 
downstream (Pacher et al., 2007), another explanation for the different beneficial effects of 
agonists and antagonists in circulatory shock could reside in their various anti-inflammatory 
and/or antioxidant properties (Klein, 2005). These could be attributed to their inverse 
agonist properties or to mechanisms independent from CB1 and CB2 receptors (Pertwee, 
2006). 
In global terms, it seems clear that both cannabinoids and antagonists of CB receptors may 
exert several beneficial effects in shock models in rats; however, the specificity of these 
effects and their importance for the circulatory shock in humans requires further 
investigation. 
Role of endocannabinoid system in hypertension  
The potential use of cannabinoid ligands as antihypertensive agents was even considered 
since 1970 (Archer, 1974; Birmingham, 1973), and were further reviewed (Sarzani, 2008; 
Pacher et al., 2005). Cannabinoids decrease blood pressure in hypertensive rodents 
primarily because of decrease cardiac contractility, suggesting that could have a therapeutic 
role on hypertension and cardiac hypertrophy. Rimonabant, the CB(1) receptor blocker 
induced a significant increase in cardiac contractility and blood pressure in hypertensive 
rats but, on the contrary, contributed to decrease blood pressure in weight-loss clinical trials 
especially in obese patients with hypertension, which suggests that the overactivation of the 
ECS in intra-abdominal obesity could be a deleterious effect, in particular from a 
cardiometabolic opinion (Sarzani, 2008). In addition to the studies in animal models that 
were already mentioned, it was found that inhalation of THC causes a greater and more 
lasting fall in blood pressure in hypotensive subjects when compared with normotensive 
subjects (Crawford et al., 1979). Although the mechanism underlying this increased 
sensitivity is not cleared yet, it suggests a role of endocannabinoid system in the regulation 
of cardiovascular functions in hypertension. In a recent study, using three different 
experimental models of hypertension to explore this possibility, the authors found a 
significant endocannabinergic tone in hypertension that limits the blood pressure rise and 
cardiac contractility through the activation of cardiac and vascular CB1 receptors (Bátkai et 
al., 2004b). It was also found, that over-regulation of these same receptors contributes to 
potentiate of this tone, maybe trough the inhibition of the activation of endogenous 
anandamide, stabilizing blood pressure and the contractility of the heart in hypertension. 
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These findings contribute to the interesting possibility of using inhibitors of fatty acid amide 
hydrolase in the treatment of hypertension. More clinical studies will be needed to clarify 
this interesting possibility in a near future. 
Role of endocannabinoid system in atherosclerosis  
Cannabinoids, endogenous and synthetic, have complex cardiovascular actions through the 
activation of CB1 receptors (vascular and myocardial) (Steinberg et al., 2007). The decline of 
cardiac function associated with age and the changes in inflammation genes expression, 
nitrative stress and apoptosis in rats FAAH-/- compared with wild type rats was analyzed 
(Batkai et al., 2007; Mach & Steffens, 2008). The authors found that increased levels of 
anandamide in FAAH-/- rats have a protective effect, which is consistent with the protective 
role of cannabinoids in inflammatory disorders, such as atherosclerosis. Besides that, 
anandamide demonstrated its capacity to attenuate, in a dose-dependent manner, the 
expression of ICAM-1, induced by TNF-α, and of VCAM-1 in endothelial cells of human 
coronary arteries, and also THP-1 monocytes adhesion in a process dependent on CB1 and 
CB2 receptors (Batkai et al., 2007). Contrary to the potential beneficial effect in 
cardiovascular disease, the endocannabinoids may exhibit some prothrombotic effects. In 
fact, both anandamide and 2-AG were described as activators of human and rodent 
platelets. The platelets are cellular anucleated fragments that circulate on blood stream. 
Besides their recognized role in homeostasis and in thrombus formation, platelets may also 
have proinflammatory properties and be growth regulators, contributing to the progression 
of atherosclerosis (Leite et al., 2009). Endothelial cells, macrophages and platelets may, by 
itself, increase their synthesis of endocannabinoids during the formation of atherosclerotic 
plaque, leading to the activation of platelets. Alternatively, these cells are able to metabolize 
2-AG and anandamide, which can offset the increased levels of cannabinoids. CB1 blockade 
with rimonabant, besides reduce weight and abdominal adiposity, improves 
cardiometabolic profile, due to multiple influences, including increased levels of high 
density lipoprotein (HDL)-cholesterol and reduced triglycerides (Despres et al., 2005; Van 
Gaal et al., 2005). A possible role for CB2 receptors on the progression of atherosclerosis was 
suggested in an experimental model. The authors found that oral low-doses THC treatment 
could inhibit the development of atherosclerostic plaque, which was reversed using 
SR144528, an antagonist of CB2 receptors (Klein et al., 2003). The progression of 
atherosclerosis was associated with a reduced infiltration of macrophages in the 
atherosclerotic lesions. The mobilization, adhesion and trans-endothelial migration of 
leukocytes are triggered by the local production of chemokines, its receptors and adhesion 
molecules (Braunersreuther & Mach, 2006). Cannabinoids, endogenous or synthetic, have 
shown to modulate the migration of several cell types, including immune cells trough 
activation of CB2 receptors (Miller & Stella, 2008). In overall, despite some interesting 
findings, a specific role of endocannabinoid signaling during atherosclerosis remains to be 
better elucidated. 
New therapeutic opportunities of ECS in cardiovascular disorders 
Obesity remains a continuous healthy problem and research issue, which is explained by the 
serious consequences associated with it, as well as by the increasing incidence of type 2 
diabetes and associated obesity, including in younger individuals. In this way, the ECS, due 
to its well known properties of weight control and energy balance, appeared as a promising 
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target for the treatment of obesity, namely by blocking its receptors. The blockade of these 
receptors was effectively done by rimonabant, which was viewed as a promising drug for 
the treatment of obesity. Besides its action on obesity, rimonabant has also proved to be 
efficient in controlling vascular diseases in several clinical trials and, therefore, this drug 
was presented as an effective therapeutic approach for treating obesity and cardiovascular 
disease. However, despite the proven effectiveness in weight loss, rimonabant clinical use 
was associated with several side effects, which mainly includes the following three groups: 
the first one includes psychiatric disorders such as depression and anxiety; the second one is 
associated with gastrointestinal disturbances such as nausea; and finally the third group 
with regard to neurological changes that are reflected in headaches and vertigo. Despite 
these adverse effects, which originated its removal from the marker, since the blockade of 
CB1 receptors continues to prove an asset in the management of obesity and its associated 
risks (such as reduction of lipogenesis, decreased waist circumference, insulin resistance and 
dyslipidemia), research in the modulation of the ECS has continued. 
 
ENDOCANNABINOIDS
(ANANDAMINE and/or 2-AG)
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Fig. 3. Endocannabinoids pleiotropic effects on cardiovascular physiology, demonstration 
protection activity on several tissues, together with positive impact on various other cells 
that contribute to cardiovascular/atherosclerotic pathologies, such as the monocytes, 
macrophages, lymfocyttes, leucocytes, neutrophils and other inflammatory cells. 
Although CB1 receptors seem to be the main target for new therapeutic interventions, CB2 
receptors are also involved in several mechanisms and, since they are present in immune 
cells and are, apparently, involved in modulating immune responses, they are extremely 
important and may be seen as a therapeutic target as well. Several line of evidences have 
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been clearly suggesting that cannabinoids and their endogenous and synthetic analogs can 
promote important cardiac effects, which includes hypotension and cardiodepression. The 
actions seem to be mediated by complex mechanisms, including both direct and indirect 
effects both on the vasculature and on the myocardium. Furthermore, the ECS, including 
endocannabinoids and cannabinoid receptors, have been implicated in the myocardial and 
cerebral ischemia/reperfusion, in hypotensive state associated with hemorrhagic, endotoxic 
and cardiogenic shock, and in advanced liver cirrhosis. There is also promising evidences 
hypothesizing a key role for the endocannabinergic system in the cardiovascular regulation 
in hypertension, as well as a beneficial action on atherosclerotic plaque.  Resuming, 
cannabinoids are able to modulate a countless number of physiologic functions, 
demonstration a pleiotropic protective action on the cardiovascular physiology (Figure 3) 
and therefore, endocannabinoid system is a potential target for the treatment of several 
diseases and the research about this subject still have a long way to go. The evidence so far 
gathered shows that the modulation of ECS (as agonism or antagonism of its receptors) is an 
enormous potential field for research and intervention in multiple areas of human 
pathophysiology. The development of selective drugs for the CB1 and CB2 receptors may 
open a door to new therapeutic regimens, in particular in several cardiovascular disorders. 
11. Conclusion 
The recreational use of the plant Cannabis sativa and the attempt to exploit their potential 
therapeutic use have been described over the centuries. The popularity of marijuana, one of 
the most common forms of consumption as a recreational substance and as a drug, reflects 
its ability to later sensory perceptions and to reduce anxiety. Experimental studies have been 
repeatedly demonstrated 9-THC effects on an individual cognitive function and 
psychomotor skills, influencing learning and information acquisition, changing the 
individual's memory capacity, coordination and reaction times. The biggest concern with 
cannabinoids acute effects is related to road traffic or labour accidents. Indeed, 9-THC 
acute effects on cognitive function and psychomotor skills have been subject of extensive 
study, noting that, at doses between 40 and 300 mg/kg, cannabinoids can cause a dose-
dependent reduction in tasks that require memory use, reaction times, in motor functions 
and coordination. It has been shown that the influence and accident risk due to recent 
cannabis increases with dose, with an influenced state already present at low doses, being 
even worse at higher concentrations. 9-THC plasma concentrations can be very variable, 
with values between 1 and 35 ng/ml in suspected impaired drivers and between 1 and 100 
ng/ml in fatal road traffic drivers.  
Non-psychoactive actions of marijuana, like pain relief, were also described in ancient texts. 
However, the biochemical and pharmacological study of this substance has a fairly recent 
start. Endocannabinoids are involved in several physiological functions, among which, 
special attention has been given to the regulation of appetite by central mechanisms and its 
influence on obesity. Considering these innovative findings, the research for new 
pharmacological agents has drastically increased and the discovery of rimonabant, a 
synthetic antagonist of CB1 receptors, has confirmed the important role of endocannabinoid 
system on the modulation of food ingestion and energetic balance. Although several other 
different influences of EC have been discussed during the last years, including in 
inflammation, diabetes, cancer, affective and neurodegenerative diseases, and epilepsy, the 
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most recent findings are related to their cardiovascular actions, which seem to be very 
ample bust also complex. The ECS, which includes the endocannabinoids and its receptors, 
have been implicated in hypotensive stages associated with hemorrhagic chock, both 
endotoxic and cardiogenic, and even to advanced liver cirrhosis; on the other hand, recent 
evidence suggests that ECS plays an important role in cardiovascular regulation associated 
with hypertension, as well as a protective role in ischemia grafting. The development of 
atherosclerotic plaque and the metabolic stages associated to obesity are also matter of study 
of possible ECS pharmacomodulation.  
The continued approach of biophysics and molecular characterization of ligands for the 
cannabinoid receptor will contribute decisively to the success of cross-level research of ECS. 
Those advances will be pivotal for the development and definition of the profile of new 
chemical entities as therapeutic endocannabinoid modulators. They may also facilitate the 
identification of new dynamics of the ECS to be used as predictive and/or diagnostic 
orientation biomarkers for the patients, as well as therapeutic based on ECS 
pharmacomodulation. The therapeutic approach of cardiovascular system starting from the 
modulation of ECS appears to be a promising and multidisciplinary issue of study that is 
still in its early stages but that could be a field for better therapeutic intervention in several 
disorders, including of cardiovascular and cardiometabolic nature. 
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